Printer Friendly

ORTHOMET ANNOUNCES AGREEMENT TO ACQUIRE ENDOTEC

            ORTHOMET ANNOUNCES AGREEMENT TO ACQUIRE ENDOTEC
    MINNEAPOLIS, Feb. 25 /PRNewswire/ -- Orthomet, Inc. (NASDAQ: OMET)


announced that an agreement in principle has been signed to acquire the outstanding stock of Endotec, Inc.
    The estimated cost of the transaction will be $3.5 million, with approximately $2.0 million in cash and the remainder in 200,000 shares of Orthomet common stock.  Orthomet expects to finance the cash portion of the transaction via a private placement of its common stock.
    The company stated this is a strategic transaction which will strengthen its position in the reconstructive hip market, provide other state-of-the-art implants, and provide the company a continuing relationship with leading members of the orthopaedic industry -- the two principals of Endotec, Inc., Frederick F. Buechel, M.D., and Michael J. Pappas, Ph.D.
    Orthomet expects the transaction to close in the late March to early April timeframe, subject to the successful negotiation of a definitive acquisition agreement, completion of acquisition due diligence, approval of its board of directors, and successful completion of the private placement.
    Orthomet Inc. is in the business of designing, manufacturing and marketing selected orthopaedic reconstructive implant products and related surgical instrumentation.
    -0-                                    2/25/92
    /CONTACT:  James C. Hawley, vice president-finance and administration, and chief financial officer of Orthomet, 612-944-6112/
    (OMET) CO:  Orthomet Inc. ST:  Minnesota IN:  HEA SU:  TNM SH-TS -- NY012 -- 2192 02/25/92 08:50 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1992
Words:231
Previous Article:CPAC COMPLETES PRIVATE STOCK PLACEMENT
Next Article:AMERICAN BIOGENETIC SCIENCES FIBRINOGEN ANTIBODY PATENT NO. 5,091,512 ISSUED
Topics:


Related Articles
ORTHOMET, INC. RECEIVES FDA APPROVAL FOR EXTENSION TO KNEE PRODUCT LINE; BEGINS TRIAL DISTRIBUTION IN U.S. OF 3M SHOULDER PRODUCT
ORTHOMET ANNOUNCES TERMINATION OF DISCUSSION WITH ENDOTEC
ORTHOMET ANNOUNCES NEW CONTRACT WITH CHAIRMAN AND CEO
ORTHOMET ENTERS FIVE-YEAR AGREEMENT TO DISTRIBUTE 3M RECONSTRUCTIVE SHOULDER PRODUCTS
ORTHOMET AND KIRSCHNER SIGN LETTER OF INTENT TO MERGE
ORTHOMET ANNOUNCES MERGER AGREEMENT WITH WRIGHT
ORTHOMET AND WRIGHT MEDICAL TECHNOLOGY, INC. SIGN LETTER OF INTENT TO MERGE
WRIGHT MEDICAL TECHNOLOGY, INC. EXTENDS ORTHOMET TENDER OFFER
WRIGHT MEDICAL TECHNOLOGY SUCCESSFULLY COMPLETES TENDER OFFER FOR ALL OUTSTANDING COMMON AND 6% CONVERTIBLE PREFERRED STOCK OF ORTHOMET
WRIGHT MEDICAL TECHNOLOGY SUCCESSFULLY COMPLETES TENDER OFFER FOR ALL OUTSTANDING COMMON AND 6% CONVERTIBLE PREFERRED STOCK OF ORTHOMET

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters